Regulation
97 blogs about the topic
An Excellent 12th GHTF Conference explores answers on the future of the GHTF
Just sitting at the airport after what was an excellent Global Harmonization Task Force Conference. Well done Steve Dibert and his crew, not to mention Health Canada. Who says regulatory affairs is boring! This conference really put the moose among the pigeons! We had a truly gripping opening session from Dr. Robert Jackson, the renowned […]
Posted on 15.04.2009
BVMed goes Brussels
Last night I attended BVMed’s well attended debate looking at the German medical technology sector in times of the economic crisis. The debate was hosted by the permanent representation of the German Federal State of North Rhine Westfalia. Member of the European Parliament, Dr Peter Liese, was one of the speakers. He welcomed BVMed’s initiative […]
Posted on 14.04.2009
One of the great untold strengths of device regulation in Europe
Just back from Easter holidays and picked up this article from the Wall Street Journal “Medical Devices Face New Scrutiny From FDA”. When I read the article it reminded me again of one of the great untold strengths of device regulation in Europe and yet another example where the European system is better than the […]
Eucomed press release 05/09 – Revised Directive on Late payments: 23.6 billion Euros of unpaid invoices threaten small companies’ survival and jeopardize public health
Brussels, 8 April 2009 – Eucomed welcomes revision of directive 2000/35/EC on Late Payments adopted by the European Commission today strengthening current payment obligations. Association disappointed to see final text considerably watered down compared to initial clear targets. As the voice of the medical technology industry in Europe, Eucomed is extremely pleased to see late […]
More from the DIA EuroMeeting 2009
From 23 – 25 March 2009, the Drug Information Association (DIA) held its annual EuroMeeting in Berlin. During the presentation by Richard Moore, Institute of Nanotechnology, I learned that prescription drugs prove to be ineffective in 30% – 60% of patients1 and that 16% of the drugs approved in the USA are linked to severe […]
Patient Power across Europe
On one of those beautiful clear Spring mornings here in Brussels, it was a rare pleasure to head out early for breakfast with the Health Consumer Powerhouse. Housed in a beautiful high ceilinged and gilt embellished office near De Brouckere, Health Consumer Powerhouse is a champion for European consumers of healthcare (you and me) and […]
The role of EMEA in future regulation: consensus amongst experts
It was with some trepidation that I placed myself in the ‘lions den’ of the pharmaceutical industry at the annual Euromeeting of the Drug Information Association in Berlin today. Sharing a platform to discuss the evolution of medical device regulation with Mdme Georgette Lalis of the EU Commission and David Feigal, former FDA Commissioner, proved […]